Concert Pharmaceuticals Inc
NASDAQ:CNCE
Intrinsic Value
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CNCE.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Concert Pharmaceuticals Inc's business.
What risks and challenges
does Concert Pharmaceuticals Inc face in the near future?
Summarize the latest earnings report
of Concert Pharmaceuticals Inc.
Provide P/E
for Concert Pharmaceuticals Inc and its competitors.
Balance Sheet Decomposition
Concert Pharmaceuticals Inc
Current Assets | 157.2m |
Cash & Short-Term Investments | 149.5m |
Receivables | 1.6m |
Other Current Assets | 6m |
Non-Current Assets | 13.9m |
PP&E | 12.8m |
Other Non-Current Assets | 1.2m |
Current Liabilities | 17.4m |
Accounts Payable | 2.7m |
Accrued Liabilities | 4.7m |
Other Current Liabilities | 9.9m |
Non-Current Liabilities | 20.5m |
Other Non-Current Liabilities | 20.5m |
Earnings Waterfall
Concert Pharmaceuticals Inc
Revenue
|
42k
USD
|
Operating Expenses
|
-160.3m
USD
|
Operating Income
|
-160.3m
USD
|
Other Expenses
|
-3.7m
USD
|
Net Income
|
-164m
USD
|
Free Cash Flow Analysis
Concert Pharmaceuticals Inc
What is Free Cash Flow?
CNCE Profitability Score
Profitability Due Diligence
Concert Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Concert Pharmaceuticals Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
CNCE Solvency Score
Solvency Due Diligence
Concert Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Concert Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CNCE Price Targets Summary
Concert Pharmaceuticals Inc
Ownership
CNCE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CNCE Price
Concert Pharmaceuticals Inc
Average Annual Return | -20.9% |
Standard Deviation of Annual Returns | 55.92% |
Max Drawdown | -79% |
Market Capitalization | 401.2m USD |
Shares Outstanding | 48 022 600 |
Percentage of Shares Shorted | 2.43% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2014-02-13. The firm is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The firm is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The firm is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.